Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

Summary

The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.

Timeline

Start

2017-10-03

Primary completion

2019-05-20

Completion

2019-05-20

Outcome

Met primary endpoint

registry analysis (superiority test); Anaferon for Children vs Placebo; p = 0.001; Regression, Logistic NCT03301155 ↗

registry analysis (superiority test); Anaferon for Children vs Placebo; p = 0.0218; Hazard Ratio (HR) 0.645 (95% CI 0.496 to 0.839); Regression, Cox NCT03301155 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anaferon for Children	Unknown	—	Oral

Indications

No indication recorded.